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Long-Term Survival After Aortic Valve Replacement
Influence of Age, Obesity, and Left Ventricular Dysfunction
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Patrick Mathieu, MD, FRCS,* François Dagenais, MD, FRCS,* Pierre Voisine, MD, FRCS,*
Philippe Pibarot, DVM, PHD, FACC, FAHA*
Québec, Québec, Canada; and Tours, France
Objectives This study was designed to evaluate the effect of valve prosthesis-patient mismatch (PPM) on late survival after
aortic valve replacement (AVR) and to determine if this effect is modulated by patient age, body mass index
(BMI), and pre-operative left ventricular (LV) function.
Background We recently reported that PPM is an independent predictor of operative mortality after AVR, particularly when
associated with LV dysfunction.
Methods The indexed valve effective orifice area (EOA) was estimated in 2,576 patients having survived AVR and
was used to define PPM as not clinically significant if it was 0.85 cm2/m2, as moderate if 0.65 and
0.85 cm2/m2, and severe if 0.65 cm2/m2.
Results After adjustment for other risk factors, severe PPM was associated with increased late overall mortality (hazard
ratio [HR]: 1.38; p  0.03) and cardiovascular mortality (HR: 1.63; p  0.0006) in the whole cohort. Severe
PPM was also associated with increased overall mortality in patients 70 years old (HR: 1.77; p  0.002) and
in patients with a BMI 30 kg/m2 (HR: 2.1; p  0.006), but had no impact in older patients or in obese pa-
tients. Moderate PPM was a predictor of mortality in patients with LV ejection fraction 50% (HR: 1.21; p 
0.01), but not in patients with preserved LV function.
Conclusions Moderate PPM is associated with increased late mortality in patients with LV dysfunction, but with normal prog-
nosis in those with preserved LV function. Notwithstanding the previously demonstrated deleterious effect of se-
vere PPM on early mortality, this factor appears to increase late mortality only in patients 70 years old and/or
with a BMI 30 kg/m2 or an LV ejection fraction 50%. (J Am Coll Cardiol 2009;53:39–47) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.09.022p
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salve prosthesis-patient mismatch (PPM) is present when
he effective orifice area (EOA) of the inserted prosthetic
alve is too small in relation to body size (1,2). Its main
emodynamic consequence is to generate higher than ex-
ected gradients through normally functioning prosthetic
alves. There have been some discrepancies in the published
eports about the impact of PPM on post-operative out-
omes. Several studies reported that PPM is an independent
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ccepted September 15, 2008.redictor of cardiac events and mortality after aortic valve
eplacement (AVR) (3–7); others failed to demonstrate a
igificant effect of PPM on post-operative outcomes (8–12).
hese discrepancies may be explained, at least in part, by the
act that the investigators used different parameters and
riteria to identify PPM and quantify its severity (13,14).
lso, these discrepancies may be related to differences in the
aseline characteristics of the patient populations included
n these studies. Several factors including age, body mass
ndex (BMI), and pre-operative status of left ventricular
LV) function may potentially influence the effect of PPM
n post-operative outcomes.
We previously reported that PPM is associated with
ncreased operative mortality after AVR, particularly when
ssociated with LV dysfunction (5). The objective of this
tudy was to evaluate the effect of PPM on late survival after
VR in a large series of patients and to determine if this
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age, BMI, and pre-operative LV
function.
Methods
Eligibility criteria. All patients
who underwent a first AVR with
or without coronary artery bypass
grafting surgery (CABG) at La-
val Hospital between January
1992 and December 2005 were
eligible for this study. Of the
2,820 eligible patients, those
(n  167; 6%) who died during
or within 30 days of surgery were
excluded. Moreover, PPM could
not be assessed in 77 (3%) pa-
tients because data on normal
reference EOA were not avail-
ble. The study population was thus composed of 2,576
atients (mean age 68.5  10 years; 61% male). Fifty-six
ercent of these patients received a stented bioprosthesis,
2% received a stentless bioprosthesis, 22% received a
echanical prosthesis, and 44% underwent concomitant
ABG. Table 1 shows the distribution of the prosthesis
odels implanted in this series. Contemporary models were
sed in 95% of these patients.
ata collection. Clinical, operative, and outcomes data
ere prospectively collected and validated. Database was
ueried retrospectively. Survival data were obtained from
he death certificates of the Registry Office of the Quebec
overnment. Follow-up information was available in 98%
f the patients. LV ejection fraction was available in 2,361
92%) of the patients.
Normal Reference Values of Effective Orifice Areas f
Table 1 Normal Reference Values of Effective O
Prostheses Patients, n (%)
Aortic stented bioprostheses
Medtronic Intact 133 (5)
Medtronic Mosaic 712 (28)
Medtronic Hancock II 49 (2)
Carpentier-Edwards Perimount 183 (7)
Carpentier-Edwards Magna 293 (11)
Mitroflow 108 (4)
Aortic stentless bioprostheses
Medtronic Freestyle 520 (20)
St. Jude Medical Toronto SPV 59 (2)
Cryolife O’Brien 6 (0.2)
Aortic mechanical prostheses
St. Jude Medical Standard 321 (12)
St. Jude Medical Regent 129 (5)
MCRI On-X 85 (3)
Medtronic Advantage 50 (2)
Abbreviations
and Acronyms
AVR  aortic valve
replacement
BMI  body mass index
BSA  body surface area
CABG  coronary artery
bypass graft
CI  confidence interval
EOA  effective orifice
area
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular
ejection fraction
PPM  valve prosthesis-
patient mismatchPM definition. The projected indexed EOA was derived
rom the published normal in vivo EOA values for each
odel and size of prosthesis implanted in this cohort (Table
) (15–21), as previously described and validated (13,22).
PM was defined as not clinically significant if the projected
ndexed EOA was 0.85 cm2/m2, as moderate if it was
0.65 and 0.85 cm2/m2, and as severe if it was 0.65
m2/m2.
tatistical methods. Results are expressed as mean  SD
r percentages unless otherwise specified. The cohort was
ivided into 3 groups according to PPM severity: nonsig-
ificant, moderate, and severe. Baseline data were compared
or statistical significance using a 1-way analysis of variance,
hi-square, and Fisher exact test when the number of
atients in 1 category was 5.
Cumulative probability of survival was estimated with the
aplan-Meier method and compared between groups by
sing a log-rank test. Cox proportional-hazards regression
odels were used to determine whether moderate and
evere PPM were associated with survival after adjusting for
otential confounding variables. Clinically relevant variables
nd those with a value of p 0.1 on univariate analysis were
ncorporated into the multivariate models. Additional anal-
sis was performed to control for selection bias potentially
elated to PPM. A propensity score representing the likeli-
ood of having severe PPM was calculated for each patient
y using a logistic regression analysis that identified vari-
bles independently associated with severe PPM. Variables
ncluded in the logistic regression analysis were: sex, BMI,
iabetes, predominant aortic stenosis, prosthesis size 21
m, prosthesis type (bioprosthesis vs. mechanical valve),
nd cardiopulmonary bypass time. The propensity score was
hen incorporated into subsequent proportional-hazards
odels. All statistical analyses were performed with a
stheses Implanted in This Series
Areas for Prostheses Implanted in This Series
Prosthetic Valve Size, mm
Ref. #21 23 25 27 29
1.0 1.3 1.4 1.7 2.0 —
1.2 1.4 1.7 1.8 2.0 (15)
1.2 1.3 1.5 1.6 1.6 (15)
1.3 1.5 1.8 2.1 2.2 (15)
1.7 2.1 2.3 — — (17,18)
1.3 1.5 1.8 — — (19)
1.4 1.5 2.0 2.3 — (15)
1.3 1.5 1.7 2.1 2.7 (15)
1.2 1.6 1.9 2.0 2.2 (20)
(15)
1.4 1.5 2.1 2.7 3.2 (15)
2.0 2.2 2.5 3.6 4.4 (16)
1.7 2.0 2.4 3.2 3.2 (16)
1.7 2.2 2.8 3.3 3.9 (21)or Pro
rifice
19
0.9
1.1
1.1
1.1
1.3
1.1
1.2
—
—
1.0
1.6
1.5
—
Carbomedics Standard 5 (0.2) 1.0 1.5 1.7 2.0 2.5 2.6 (15)
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December 30, 2008/January 6, 2009:39–47 Impact of Prosthesis-Patient Mismatch on Survivalommercially available software package JMP IN 5.1 (SAS
nstitute Inc., Cary, North Carolina).
esults
oderate PPM was present in 31% of patients and severe
PM in 2%. Pre-operative and operative data are shown in
able 2. Compared with patients with nonsignificant PPM,
hose with moderate or severe PPM had a larger BMI and
higher prevalence of female sex, hypertension, diabetes
ellitus, and coronary artery disease, as well as a history of
enal failure, predominant aortic stenosis, and small pros-
hesis size (21 mm). Patients with moderate PPM, but
ot those with severe PPM, were significantly older com-
ared with patients with nonsignificant PPM. Mechanical
rosthesis implantation was more frequent in the severe
PM group than in the moderate or nonsignificant PPM
roups. In a subset of 496 patients in whom a Doppler-
chocardiographic examination was performed 1 month
fter operation in our institution, the measured indexed
OAs were very similar to the projected indexed EOAs in
he same groups, and the peak and mean transprosthetic
radients were significantly higher in patients with PPM,
Baseline Pre-Operative and Operative Dataas a Function of the Severity of Prosthesis-Patie
Table 2 Baseline Pre-Operative and Operativas a Function of the Severity of Pro
Variables
Nonsignifcant P
(n  1,739)
Pre-operative data
Age, yrs 68 10
Female, % 33
BSA, m2 1.8 0.2
BMI, kg/m2 26 5
CAD, % 57
NYHA functional class III to IV, % 61
Hypertension, % 54
Diabetes, % 18
Renal failure, % 10
Chronic lung disease, % 19
TIA/stroke, % 8
Predominant AS, % 54
LVEF, % 59 15
LVEF 50%, % 19
Operative data
Mechanical prosthesis, % 24
Prosthesis size 21 mm, % 16
Concomitant CABG, % 43
CPB time, min 116 40
Projected EOAI, cm2/m2 1.1 0.2
Post-operative (1-month) data
EOAI, cm2/m2‡ 1.1 0.2
PPeak, mm Hg‡ 22 8
PMean, mm Hg‡ 11 4
Data are mean  SD or percentage of patients. *Significant differenc
group. ‡These data were available in a subset of 496 patients.
AS aortic stenosis; BMI body mass index; BSA body surface a
CPB cardiopulmonary bypass; PPeak and PMean peak and mean
ventricular ejection fraction; NS  not significant; NYHA  New York Hear
ischemic accident.nd especially those with severe PPM, compared with those
ith nonsignificant PPM (Table 2).
mpact of PPM on mortality. Mean follow-up was 4.8 
.4 years (median, 4.3 years; maximum, 14 years). There
ere 559 deaths during follow-up. Late survivals were 79 
% at 5 years and 59  2% at 10 years. For patients with
evere PPM, 5-year (74  8%) and 10-year survival (40 
0%) were significantly lower than for patients with non-
ignificant PPM (5-year survival: 84 1%; 10-year survival:
1  2%; p  0.01) (Fig. 1A). There was also a trend (p 
.06) toward lower survival in the severe PPM group when
ompared with the moderate PPM group (5-year survival:
1  2%; 10-year survival: 57  3%) and in the moderate
PM group when compared with the nonsignificant PPM
roup (p  0.055).
Among the 559 deaths, 259 (46%) were classified as
eing of cardiovascular cause. Freedom from cardiovascular-
elated death was 92  1% at 5 years and 79  2% at 10
ears in the whole series, and it was significantly lower in
atients with severe PPM (5-year: 78  7%; 10-year: 50 
1%) than in those with moderate PPM (5-year: 90  1%;
0-year: 77  3%; p  0.0004) and in those with nonsig-
ismatch
ta
is-Patient Mismatch
Moderate PPM
(n  797)
Severe PPM
(n  40) p Value
71 9* 69 11 0.0001
50* 67*† 0.0001
1.8 0.2 1.9 0.3*† 0.0001
29 5* 32 7*† 0.0001
63* 75 0.0003
68* 67 0.0001
59* 68*† 0.0001
28* 35*† 0.0001
13* 18*† 0.0001
19 15 NS
6 10 NS
63* 72*† 0.0001
60 14 62 13 NS
17 18 NS
14 43*† 0.0001
38* 80*† 0.0001
46 58 NS
117 51 132 56*† 0.05
0.8 0.05* 0.6 0.04*† 0.0001
0.8 0.06* 0.6 0.08*† 0.0001
27 9* 37 16*† 0.0001
15 5* 21 9*† 0.0001
onsignificant PPM group; †significant difference with moderate PPM
BG coronary artery bypass grafting; CAD coronary artery disease;
rosthetic gradients; EOAI indexed effective orifice area; LVEF leftnt M
e Da
sthes
PM
e with n
rea; CA
transpt Association; PPM  prosthesis-patient mismatch; TIA  transient
n
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Impact of Prosthesis-Patient Mismatch on Survival December 30, 2008/January 6, 2009:39–47ificant PPM (5-year: 93  1%; 10-year: 81  2%; p 
.0001) (Fig. 1B).
redictors of mortality. On univariate analysis (Table 3),
he predictors of late post-operative overall mortality were
lder age, coronary artery disease, hypertension, diabetes,
istory of renal failure, history of chronic obstructive pul-
0 2 4 6 8 10 12
Overall Survival (%)
P = 0.008
Years
0
100
20
40
60
80
1286    898     561      329      175       77
594     444     294      159       78        35
29       22       15        11         8          2 
A
Figure 1 Late Overall Survival and Freedom From Cardiovascula
Brown line indicates nonsignificant prosthesis-patient mismatch (PPM); green line
nivariate and Multivariate Predictors of Late Overall Mortality
Table 3 Univariate and Multivariate Predictors of Late Overall M
Variables
Univariate Analysis
p Value HR (95% CI)
Pre-operative variables
Age, yrs 0.0001 1.06 (1.05–1.08)
Sex 0.41 0.96 (0.89–1.04)
BMI, kg/m2 0.009 0.97 (0.95–0.99)
NYHA functional class III to IV 0.04 1.22 (1.01–1.49)
LVEF, % 0.0001 0.99 (0.98–0.99)
CAD 0.0001 1.22 (1.11–1.33)
Hypertension 0.0006 1.15 (1.05–1.26)
Diabetes 0.0001 1.25 (1.14–1.38)
Renal failure 0.0001 1.51 (1.38–1.67)
Chronic lung disease 0.0001 1.43 (1.31–1.57)
Predominant AS 0.09 0.93 (0.085–1.02)
Operative variables
Prosthesis (21 mm) 0.28 1.06 (0.96–1.17)
Concomitant CABG 0.04 1.19 (1.00–1.40)
Mechanical prosthesis 0.0008 1.16 (1.06–1.27)
Moderate PPM 0.09 1.07 (0.99–1.17)
Severe PPM 0.01 1.44 (1.01–1.97)
Propensity score 0.01 2.33 (1.16–4.76)old indicates statistical significance on multivariate analysis. Model #1: without adjustment for propens
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 2.onary disease, reduced LV ejection fraction (LVEF), the
se of a mechanical prosthesis, and severe PPM (age-
djusted hazard ratio [HR]: 1.44; 95% confidence interval
CI]: 1.19 to 1.97; p  0.01). Moderate PPM also tended
o be associated with higher mortality on univariate analysis
age-adjusted HR: 1.07; 95% CI: 0.99 to 1.17; p  0.06).
0 2 4 6 8 10 12
Freedom From Cardiovascular
Death (%)
P < 0.0001
Years
1286    898     561      329      175       77
594     444     294      159       78        35
29       22       15        11         8          2 
0
0
0
0
0
0
ath
tes moderate PPM; orange line shows severe PPM.
lity
Multivariate Analysis
Model #1 Model #2
Value HR (95% CI) p Value HR (95% CI)
0.0001 1.06 (1.05–1.08) <0.0001 1.06 (1.05–1.08)
0.60 0.97 (0.87–1.09) 0.77 0.98 (0.87–1.10)
0.11 0.98 (0.96–1.0) 0.26 0.97 (0.92–1.02)
0.43 1.08 (0.88–1.35) 0.43 1.08 (0.88–1.36)
0.004 0.99 (0.98–0.99) 0.003 0.99 (0.98–0.99)
0.01 1.12 (1.01–1.24) 0.02 1.12 (1.01–1.24)
0.54 1.03 (0.93 to 1.13) 0.53 1.03 (0.93–1.13)
0.0001 1.24 (1.11–1.39) 0.0001 1.24 (1.12–1.38)
0.0001 1.26 (1.13–1.41) 0.0001 1.26 (1.12–1.41)
0.0001 1.34 (1.21–1.48) <0.0001 1.37 (1.24–1.50)
0.65 1.02 (0.92–1.12) 0.89 1.00 (0.90–1.12)
0.97 0.99 (0.87–1.14) 0.68 1.05 (0.82–1.33)
0.07 0.79 (0.62–1.01) 0.06 0.78 (0.61–1.0)
0.87 1.01 (0.88–1.15) 0.8 1.01 (0.88–1.17)
0.65 0.97 (0.88–1.08) 0.64 0.99 (0.89–1.09)
0.03 1.38 (1.03–1.7) 0.04 1.34 (1.01–1.70)
— — 0.59 1.45 (0.66–3.23)10
2
4
6
8
B
r De
indicaorta
p
<
<ity score. Model #2: with adjustment for propensity score.
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December 30, 2008/January 6, 2009:39–47 Impact of Prosthesis-Patient Mismatch on Survivaln multivariate analysis (Table 3), after adjusting for the
ariables with a p value 0.1 on univariate analysis as well
s for sex and BMI, severe PPM was independently asso-
iated with increased late mortality (HR: 1.38; 95% CI: 1.03
o 1.77; p  0.03); moderate PPM did not come out as an
ndependent predictor. After further adjustment for the
ropensity score, severe PPM remained significantly asso-
iated with increased mortality (HR: 1.34; 95% CI: 1.01 to
.70; p  0.04) (Table 3).
Also, severe PPM was independently associated with
ncreased cardiovascular mortality on univariate (age-
djusted HR: 1.80; 95% CI: 1.32 to 2.32; p  0.0005) and
ultivariate (HR: 1.63; 95% CI: 1.15 to 2.20; p  0.0006
nd HR: 1.55; 95% CI: 1.16 to 2.25; p  0.005 after
djustment for propensity score) analyses; moderate PPM
as not (Table 4).
nteraction between PPM and age, BMI, and LV ejec-
ion fraction. There was a significant interaction between
PM and age (Figs. 2A and 2B). Indeed, severe PPM was
ssociated with increased overall mortality in the subset of
atients 70 years old (HR: 1.77; 95% CI: 1.1 to 2.58; p 
.02), but had no significant effect on survival in older
atients. After adjustment for other risk factors and for
ropensity score, severe PPM was associated with a 1.77-
old increase in mortality (95% CI: 1.24 to 2.39; p  0.002)
n the patients 70 years old.
Furthermore, there was also an interaction between PPM
nd BMI (Figs. 2C and 2D). Severe PPM had a highly
ignificant impact on survival (age-adjusted HR: 1.59; 95%
I: 1.13 to 2.09; p  0.008) in the subset of patients (n 
,986; 75%) with a BMI 30 kg/m2. However, this effect
as no longer significant in the obese patients (BMI 30
nivariate and Multivariate Predictors of Late Cardiovascular Mort
Table 4 Univariate and Multivariate Predictors of Late Cardiova
Variables
Univariate Analysis
p Value HR (95% CI)
Pre-operative variables
Age, yrs 0.0001 1.08 (1.06–1.09)
Sex 0.07 0.89 (0.79–1.01)
BMI, kg/m2 NS 1.006 (0.98–1.03)
NYHA functional III to IV 0.03 1.36 (1.02–1.85)
LVEF, % 0.0001 0.98 (0.97–0.99)
CAD 0.0001 1.39 (1.22–1.59)
Hypertension 0.0002 1.27 (1.11–1.44)
Diabetes 0.0001 1.32 (1.15–1.51)
Renal failure 0.0001 1.57 (1.36–1.80)
Chronic lung disease 0.0001 1.34 (1.17–1.53)
Operative variables
Prosthesis (21 mm) 0.03 1.17 (1.01–1.35)
Concomitant CABG 0.001 1.51 (1.18–1.94)
Mechanical prosthesis 0.09 0.88 (0.75–1.01)
Moderate PPM 0.11 1.10 (0.97–1.25)
Severe PPM 0.0005 1.80 (1.32–2.32)
Propensity score 0.49 1.43 (0.53–4.17)old indicates statistical significance on multivariate analysis. Model #1: without adjustment for propens
Abbreviations as in Tables 2 and 3.g/m2). After adjustment for other risk factors and for
ropensity score, severe PPM was associated with a 2.1-fold
95% CI: 1.26 to 3.19; p  0.006) increase in mortality in
atients with a BMI 30 kg/m2.
Moderate-to-severe PPM (indexed EOA 0.85 cm2/m2)
as an independent predictor of late mortality in patients
ith a pre-operative LVEF 50% (age-adjusted HR: 1.22;
5% CI: 1.05 to 1.41, p 0.007; HR adjusted for other risk
actors and for propensity score: 1.21; 95% CI: 1.03 to 1.41,
 0.01), but not in patients with preserved LV systolic
unction (p  NS) (Figs. 2E and 2F). The number of
atients with LV dysfunction and severe PPM was too small
o allow for separate analysis in these patients. This can
ikely be attributed to the fact that a large proportion of the
atients having concomitant pre-operative LV dysfunction
nd severe PPM died in the early post-operative period (5)
nd were therefore excluded from this study. When exclud-
ng the patients with severe PPM from the analysis, mod-
rate PPM remained significantly associated with increased
ortality (age-adjusted HR: 1.17; 95% CI: 1.01 to 1.37,
 0.04; HR adjusted for other risk factors and for
ropensity score: 1.18; 95% CI: 1.01 to 1.37, p  0.03).
iscussion
ne important finding of this study is that severe PPM is an
ndependent predictor of late mortality in patients under-
oing AVR. The results of this study also confirm previous
ata (5,23,24) showing that even a moderate PPM has a
etrimental impact on post-operative survival in the context
f a depressed LV function. Moreover, the results of this
tudy show that the impact of PPM on late survival differs
ar Mortality
ultivariate Analysis Model #1 Multivariate Analysis Model #2
Value HR (95% CI) p Value HR (95% CI)
.0001 1.07 (1.05–1.09) <0.0001 1.07 (1.05–1.09)
.53 0.95 (0.80–1.12) 0.72 0.97 (0.82–1.15)
.63 1.01 (0.97–1.03) 0.35 0.96 (0.89–1.04)
.11 1.30 (0.94–1.86) 0.11 1.31 (0.93–1.87)
.0002 0.98 (0.97–0.99) 0.0002 0.98 (0.97–0.99)
.002 1.27 (1.09–1.49) 0.02 1.26 (1.08–1.48)
.53 1.05 (0.90–1.21) NS 1.05 (0.90–1.21)
.01 1.22 (1.04–1.43) 0.007 1.26 (1.06–1.48)
.004 1.28 (1.07–1.50) 0.007 1.26 (1.06–1.49)
.001 1.28 (1.10–1.49) 0.001 1.28 (1.10–1.49)
.64 1.04 (0.85–1.28) 0.21 1.25 (0.88–1.75)
.63 0.91 (0.64–1.33) 0.56 0.89 (0.62–1.31)
.07 1.20 (0.98–1.46) 0.05 1.22 (0.99–1.48)
.67 0.96 (0.82–1.13) 0.63 0.96 (0.82–1.15)
.0006 1.63 (1.15–2.20) 0.005 1.55 (1.17–2.25)
— — 0.22 1.04 (0.33–3.33)ality
scul
M
p
<0
0
0
0
0
0
0
0
0
0
0
0
0
0
0ity score. Model #2: with adjustment for propensity score.
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ew findings emphasize the importance of tailoring the
PM preventive strategy to the baseline characteristics of
he patient.
omparison with previous studies. The results of the
resent study are consistent with those from several previous
tudies showing that PPM, and especially severe PPM,
ignificantly affects late survival (3,4,6,25,26). On the other
and, other studies reported no significant association
etween PPM and survival (8–12). The discrepancies
mong the previous studies may be, at least in part, due to
he fact that some of these studies (8–10) have identified
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ations may also help explain the discrepancies observed
mong previous studies. To this effect, studies conducted in
ounger patient populations (3,25) generally found that
PM has a significant impact on late survival; studies in
lderly populations (11,12) often failed to demonstrate any
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December 30, 2008/January 6, 2009:39–47 Impact of Prosthesis-Patient Mismatch on Survivalnteraction between PPM and age. The results of this
tudy reveal that severe PPM has a significant negative effect
n late survival in patients 70 years old, but not in the
lderly population. These results are consistent with those of
oon et al. (7), suggesting that the impact of PPM on
ost-operative outcomes is more pronounced in young
atients than in older ones. This finding might be related to
he fact that younger patients have higher cardiac output
equirements. They indeed have higher basal metabolic
ates and are generally more physically active. Also, because
hey have a longer life expectancy, younger patients are
xposed to the risk of PPM for a longer period of time.
A possible explanation for the late effect of PPM on
urvival could be that patients with PPM undergoing
ong-term bioprosthetic valve degeneration or development
f pannus have less EOA “reserve” and will therefore
evelop severe stenosis of their valves more rapidly than
atients without PPM undergoing the same processes. This
dditive effect of PPM and acquired prosthesis dysfunction
ay likely be more important in younger patients given that
hey are at higher risk for rapid calcific degeneration of their
ioprosthetic valve. Also, older patients might be more
ikely to die from other causes before this process has any
mpact. These hypothetical mechanisms, however, remain
o be confirmed by further studies.
nteraction between PPM and obesity. An important
nding of this study is that the PPM has an important
egative impact on survival in patients with a BMI 30
g/m2, but no significant impact in obese patients. This
nding is most likely related to the fact that the use of the
ody surface area for normalization of EOA may overesti-
ate the prevalence and severity of PPM in obese patients.
uture studies will be necessary to determine if the index-
tion of EOA can be improved or refined in the case of
bese patients. In this regard, the investigators of the Strong
eart Study reported that fat-free mass, which represents
he metabolically active tissues, accounts for 20% to 40%
f the weight difference between lean and obese individ-
als of the same height (28). They also demonstrated that
troke volume and cardiac output are more strongly related
o fat-free mass than to adipose mass or other anthropo-
etric measures. Hence, a potentially interesting avenue
ould be to index the EOA for the fat-free mass since this
arameter appears to be the main determinant of cardiac
utput in normal-weight, overweight, and obese people.
nteraction between PPM and LV function. From the
tandpoint of pathophysiology, it is logical to consider that
atients with reduced ventricular reserve are more vulnera-
le to the residual afterload excess imposed by PPM on the
V. Previous studies from this laboratory (5) have shown
ncreased early mortality in patients with a combination of
oderate PPM and LV dysfunction as well as in all patients
ith severe PPM, irrespective of LV function. Mortality
lso tended to be increased in patients with moderate PPM
ithout LV dysfunction, but this result was not statistically
ignificant (5). Studies from other laboratories (23,24) also wemonstrated that the impact of moderate PPM on mid-
erm mortality is more important in patients with pre-
xisting LV dysfunction than in those with preserved LV
unction. The question that we aimed to answer in the
ontext of the present study was as follows: could there be a
atural selection process in the sense that patients with
evere PPM having survived operation could have a rela-
ively good long-term prognosis? Or on the other hand, do
hey continue to have a worse prognosis? The results of this
tudy, in fact, reveal that patients with moderate PPM and
reserved pre-operative LV systolic function continue to
ave a good prognosis, similar to that in patients without
PM; those with moderate or severe PPM and LV dys-
unction continue to have worse prognoses in the long term.
oreover, the present study shows that severe PPM is also
ssociated with increased late mortality independently of
V function, but only in patients70 years old and/or with
BMI 30 kg/m2. The latter result may suggest that PPM
as less impact in older patients and/or obese patients
ecause of lesser cardiac output requirements in relation to
ody size. On the other hand, it should not be interpreted
hat the same is necessarily true with regard to early
ortality since it may well be that older and/or obese
atients are at a higher risk of early mortality, but having
urvived, would indeed have a relatively good prognosis
ecause of lesser cardiac output requirements. Further
tudies will be necessary to elucidate this point.
linical implications. As opposed to the other risk factors
or operative mortality after AVR, PPM can be avoided or
ts severity can be reduced, with the use of a preventive
trategy at the time of operation (13,18,29–31). Alternate
urgical procedures that may be considered to prevent PPM
nclude: insertion of a prosthesis with a better hemodynamic
erformance, such as a stentless bioprosthesis or a new
eneration of stented bioprosthesis or bileaflet mechanical
alve implanted in the supra-annular position; and aortic
oot enlargement to accommodate a larger size of the same
rosthesis model. This latter procedure should logically be
onsidered only in patients in whom occurrence of PPM,
nd particularly severe PPM, cannot be avoided with the use
f a better performing prosthesis and in whom the risk-
enefit ratio of doing such a procedure is considered
cceptable.
The present results corroborate previous recommenda-
ions with regard to the prevention of PPM (16), that is,
hat it should ideally be avoided in all patients with LV
ysfunction and that severe PPM should be considered as
arrying a poor prognosis regardless of LV function. On the
ther hand, it provides additional evidence that moderate
PM is well tolerated in patients without LV dysfunction.
As for the influence of age and/or BMI in patients with
nticipated severe PPM, the results should be considered, at
his time, as providing additional information and might
ecome useful in the clinical decision-making process in the
ndividual patient. Indeed, it has become apparent that
hen considering AVR, the projected indexed EOA of the
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Impact of Prosthesis-Patient Mismatch on Survival December 30, 2008/January 6, 2009:39–47rosthesis to be implanted should be routinely calculated,
nd if PPM is projected, the information should be inter-
reted in light of the patient’s clinical status including age,
ifestyle, BMI, LV function, presence of severe LV hyper-
rophy, and others, as well as the risk-benefit ratio of doing
n alternate surgical procedure. In this sense, the present
esults provide additional information, but given the dele-
erious effect of severe PPM on early mortality, even in
atients with preserved LV function, it remains to be
etermined if projected severe PPM could possibly become
cceptable in an elderly patient with a combination of
ormal LV function, limited physical activity, and other
actors significantly increasing the risk of performing an
lternate surgical procedure. Likewise, it remains to be
etermined if BMI has a similar impact on early mortality.
tudy limitations. The study is retrospective in design, so
atient characteristics in the 3 PPM groups were intrinsi-
ally different. Propensity score adjustment was used to
educe selection bias. Nonetheless, it is always possible
hat a selection bias or unidentified confounders might
ave influenced the results. On the other hand, one could
rgue that PPM is, among all the other pre-operative or
perative factors, the only one that can be easily modified
t the time of operation.
In the present study, PPM was identified with the use of
he projected indexed EOA. Previous studies demonstrated
hat this parameter correlates well with the post-operative
ndexed EOA measured by Doppler-echocardiography and
hat it provides good sensitivity and specificity for the
rediction of PPM (13,22). However, owing to various
ost-operative factors including low or high flow state condi-
ions, development of prosthesis dysfunction after implanta-
ion, and measurement errors, the post-operative EOAmay be
ubstantially different from the projected EOA in some pa-
ients. Nonetheless, in the subset of 496 patients in whom
oppler-echocardiographic exam was performed 1 month
fter operation, the measured indexed EOAs were very similar
o the projected indexed EOAs in the same groups, so it is very
nlikely that this limitation would have significantly influenced
he overall results.
Beyond the prolongation of life, the improvement of a
atient’s quality of life is also an important objective of
VR. This aspect was not addressed in the present study.
onetheless, previous studies have reported that moderate/
evere PPM is a powerful independent predictor of post-
perative functional class (32) and maximum exercise capacity
33). Hence, the results of this study on the impact of PPM on
ate survival cannot be generalized to other post-operative
utcomes such as functional outcome and early mortality.
onclusions
he present study analyzed the potential effects of moderate
nd severe PPM on late mortality in patients having
urvived AVR. Results suggest that moderate PPM is
ssociated with increased late mortality in the patients withV dysfunction, but with normal prognosis in those with
reserved LV function. Notwithstanding the previously
emonstrated strong deleterious influence of severe PPM on
perative mortality even if LV function is preserved, this
actor appears to increase late mortality only in patients70
ears old and/or with a BMI 30 kg/m2 or an LVEF
50%. Further studies are necessary to confirm the rele-
ance of this observation with regard to the clinical
ecision-making process.
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